The German API market is estimated to witness a growth rate of around 4.0% during the period of 2019–2025. Major factors that are augmenting the growth of API market in the country include rising prevalence of chronic disease which addresses the demand for API for drug production. Moreover, well-developed pharmaceutical manufacturing sector of the country is also boosting the country’s API market growth. Development in research and biopharmaceuticals has spurred the growth of the Germany’s pharmaceutical market. Bayer Schering Pharma, a globally leading specialty pharmaceutical company with 37,000 employees, focuses its research activities on four core areas such as cardiology, oncology, women’s health care, and diagnostic imaging.
Visit for Global API Market Report at: https://www.omrglobal.com/industry-reports/api-market
The German API market is segmented on the basis of type, type of synthesis, manufacturer type, therapeutics, and region. On the basis of type, the market is divided into a generic API and branded API. The branded API segment is estimated to be the dominant segment over the forecast period. On the basis of the type of synthesis, the market is classified into biotech API, synthetic API, and others. The synthetic API segment held the dominant position in the Germany API market in 2018. Furthermore, the market is classified on the basis of therapeutics into cardiovascular drugs, oncology drugs, neurology drugs, Non-steroidal Anti-inflammatory Drugs (NSAIDs), and others. NSAIDs therapeutics segment held the leading position in 2018.
Some of the prominent players that contribute significantly in the market include Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, and others. CordenPharma GmbH is one of the major German-based company. The firm is specialized in process development and route scouting mainly in the process of development for proprietary and generic APIs, high potency solid dosage forms, synthetic peptide API production, proprietary and generic API, oral and sterile oncology drug products, and drug product manufacturing. The firm has its operations laid out into various countries such as the US, UK, Brazil, and others.
Research Methodology
The market study of the German API market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for pharmaceutical and biotechnology companies, healthcare organizations, research institutes and academic institutes, pharmaceutical drug manufacturers, API manufacturers, raw material suppliers, distributors, traders, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Germany API Market by Type
5.1.1. General API
5.1.2. Branded API
5.2. Germany API Market by Type of Synthesis
5.2.1. Biotech API
5.2.2. Synthetic API
5.2.3. Others (High Potency API)
5.3. Germany API Market by Therapeutics
5.3.1. Cardiovascular Drugs
5.3.2. Oncology Drugs
5.3.3. Neurology Drugs
5.3.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.3.5. Others (Orthopedic Drugs)
6. Company Profiles
6.1. Aesica Pharmaceuticals, Ltd.
6.2. Almac group PLC
6.3. AstraZeneca PLC
6.4. Boehringer Ingelheim International GmbH
6.5. CordenPharma GmbH
6.6. Fareva SA
6.7. GlaxoSmithKline PLC
6.8. Novartis International AG
6.9. Saneca Pharmaceutical AS
6.10. Sanofi SA
6.11. Siegfried Holding AG
6.12. Teva Pharmaceutical Industries Ltd
1. GERMANY API MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. GERMANY API MARKET RESEARCH AND ANALYSIS BY TYPE OF SYNTHESIS, 2018-2025 ($ MILLION)
3. GERMANY API MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)
1. GERMANY API MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. GERMANY API MARKET SHARE BY TYPE OF SYNTHESIS, 2018 VS 2025 (%)
3. GERMANY API MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)